RevitalAge Nerve
On sale on the US market (according to the DSLD)
Pure Encapsulations, food supplement from the US market
RevitalAge Nerve (Pure Encapsulations), a food supplement au code-barres 766298014586, is described by its US market label. If sold in France, it would be subject to 1 point of French or European regulation, detailed below. Doses of folates are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine B6: up to 20 mg a day according to the label (at most 2 servings a day), above the maximum dose of 2 mg set in France for a food supplement (2006 Order, not revised since November 2006).
Source: French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), arrêté du 9 mai 2006, annexe III.
- À vérifier
Vitamine B6: up to 20 mg a day according to the label, above the tolerable upper intake level from EFSAEuropean Food Safety Authority. for adults (12 mg a day). The EFSA reference covers total daily intake, from food and supplements.
Source: EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), limite supérieure de sécurité (UL).
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Pure Encapsulations
- Barcode
- 766298014586
- Form
- Capsule
- One serving
- 2 capsules
- Servings
- up to 2 servings per day
- Other ingredients (in English, as written)
- Vegetarian Capsule, hypoallergenic Plant Fiber, Potato Starch, Ascorbyl Palmitate
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Vitamin B6 | Vitamin | 10 mg |
| Vitamin B12 | Vitamin | 250 µg |
| Folate | Vitamin | 417 µg DFE (dietary folate equivalent) |
| L-5-MTHF | Vitamin | 250 µg |
| Magnesium | Mineral | 100 mg |
| Acetyl-L-Carnitine HCl | Other substance | 500 mg |
| Alpha Lipoic Acid | Other substance | 200 mg |
| Coenzyme Q10 | Other substance | 15 mg |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: RevitalAge Nerve
Entered into DSLD on 23 April 2020. Withdrawn from the US market on 28 December 2018 (according to the DSLD).- Active ingredient added : Pyridoxal 5-Phosphate (30 mg)
- Active ingredient removed : L-5-MTHF (250 mcg)
- Active ingredient removed : Vitamin B6 (10 mg)
- Different quantity per serving : Acetyl-L-Carnitine HCl: 1,000 mg in this version; 500 mg on the displayed label
- Different quantity per serving : Alpha Lipoic Acid: 400 mg in this version; 200 mg on the displayed label
- Different quantity per serving : Coenzyme Q10: 30 mg in this version; 15 mg on the displayed label
- Different quantity per serving : Magnesium: 200 mg in this version; 100 mg on the displayed label
- Different quantity per serving : Vitamin B12: 500 mcg in this version; 250 mcg on the displayed label
- Different unit, without conversion : Folate: 500 mcg in this version; 417 mcg DFE on the displayed label
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Coenzyme Q10
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Pure Encapsulations
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “RevitalAge Nerve (Pure Encapsulations): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/766298014586-revitalage-nerve-pure-encapsulations, updated 25 February 2019.